Clinical trials: Macular Neovascularisation
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Age Related Macular Degeneration
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
The objective of the MERITAGE Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- MERITAGE (NCT00809419)
- Testing
- NeoVista Ophthalmic System
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 32 people
- Sponsor
- NeoVista
Macular Degeneration
Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)
To provide Pegaptanib sodium injection to patients with subfoveal choroidal neovascularization (CNV) secondary to AMD, who are unable to participate in any of the Sponsor's other clinical studies with this drug for AMD, until…
- Trial name
- NCT00088192
- Testing
- pegaptanib sodium
- Where
- 20 sites in United States
- Sponsor
- Eyetech Pharmaceuticals
Wet Age-related Macular Degeneration
Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
GALATIR is a double blind randomized clinical trial comparing efficacy and safety of BCD-021 (bevacizumab) and Lucentis® (ranibizumab) in patients with neovascular wet age-related macular degeneration.
- Trial name
- GALATIR (NCT02036723)
- Testing
- Bevacizumab, Ranibizumab
- Where
- 13 sites in Brazil, Russia
- Sponsor
- Biocad
Macular Degeneration, Age-Related Macular Degeneration
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person.
- Conditions
- Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
- Trial name
- MALBEC (NCT07440225)
- Testing
- Tiespectus, Aflibercept
- Where
- 132 sites in United States, Argentina and 10 more
- Volunteers
- 960 people
- Sponsor
- EyeBiotech Ltd.
Macular Degeneration
A Study of MSI-1256F (Squalamine Lactate) To Treat "Wet" Age-Related Macular Degeneration
Age-Related Macular Degeneration (AMD) is a degenerative eye disease of the retina that causes a progressive loss of central vision. AMD is the leading cause of legal blindness among adults age 50 or older in the Western world.
- Trial name
- NCT00333476
- Testing
- MSI-1256F (Squalamine Lactate)
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Genaera Corporation
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Efficacy and Safety of RTH258 Versus Aflibercept - Study 1
The purpose of this study is to compare brolucizumab (RTH258) ophthalmic solution for intravitreal (IVT) injection at two dosage levels (3 mg and 6 mg) to aflibercept ophthalmic solution for IVT injection (2 mg) in subjects with…
- Trial name
- HAWK (NCT02307682)
- Testing
- Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
- Where
- United States
- Volunteers
- 1,775 people
- Sponsor
- Alcon Research
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
- Conditions
- Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
- Trial name
- NCT03844074
- Testing
- bevacizumab, ranibizumab
- Where
- 9 sites in Australia
- Volunteers
- 61 people
- Sponsor
- Outlook Therapeutics, Inc.
Macular Degeneration
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary…
- Trial name
- NCT00090623
- Testing
- rhuFab V2 (ranibizumab)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Genentech, Inc.
Macular Degeneration, Maculopathy, Age-Related
Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
The purpose of this study was to evaluate anecortave acetate compared to placebo for maintenance of visual acuity after 24 months of treatment in patients with subfovial choroidal neovascularization (CNV) due to exudative…
- Conditions
- Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies, Age-Related Maculopathy
- Trial name
- NCT00051129
- Testing
- Anecortave Acetate 15 mg sterile suspension, Anecortave Acetate Vehicle
- Volunteers
- 291 people
- Sponsor
- Alcon Research
Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD)
A Study Of Early Markers Of Choroidal Neovascularization
Identify early markers of choroidal neovascularization (CNV) in the fellow eye of a patient with CNV in the other eye due to age-related macular degeneration with the expectation of being able to identify patients in need of…
- Conditions
- Choroidal Neovascularization (CNV), Age-related Macular Degeneration (AMD), Early Markers
- Trial name
- NCT00902785
- Testing
- no drug
- Where
- 3 sites in Italy, Portugal and 1 more
- Volunteers
- 100 people
- Sponsor
- Pfizer
Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation
VISUPRIME® Eye Drops
The study purpose is to assess the efficacy of VISUPRIME® eye drops in preventing the conjunctival bacterial load in patients undergoing to anti-VEGF injection.
- Conditions
- Macular Degeneration, Age Related, Myopic Choroidal Neovascularisation, Proliferative Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- NCT05677685
- Testing
- VISUPRIME
- Where
- 6 sites in Italy
- Volunteers
- 78 people
- Sponsor
- VISUfarma SpA
Age-related Macular Degeneration
Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration
The purpose of this study is to evaluate the safety, tolerability, and serum pharmacokinetics of CLG561 in subjects with advanced age-related macular degeneration (AMD).
- Trial name
- NCT01835015
- Testing
- CLG561
- Volunteers
- 50 people
- Sponsor
- Alcon Research
Age Related Macular Degeneration, Choroidal Neovascularization
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A.
- Trial name
- NCT00331864
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 531 people
- Sponsor
- Novartis
Macular Degeneration, Age-related Macular Degeneration
A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.
This is a two-part study to evaluate the safety, tolerability and pharmacokinetics of single (Part A) and repeat (Part B) eye drop doses of pazopanib in healthy adult and elderly subjects.
- Trial name
- NCT00463320
- Testing
- Pazopanib eye drops and Allergen Refresh Plus eye drops
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Macular Degeneration, Choroidal Neovascularization
Phase II/III Study of Anti-VEGF in Neovascular AMD
The purpose of the study is to determine whether the anti-VEGF drug is effective at stabilizing and/or improving vision in patients with the wet form of AMD
- Trial name
- NCT00021736
- Testing
- EYE001 anti-VEGF aptamer
- Where
- United States
- Volunteers
- 540 people
- Sponsor
- Eyetech Pharmaceuticals
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01944839
- Testing
- E10030, ranibizumab
- Where
- 115 sites in United States, Austria and 11 more
- Volunteers
- 619 people
- Sponsor
- Ophthotech Corporation
Age Related Macular Degeneration, Choroidal Neovascularization
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Trial name
- NCT01880788
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Sequenom, Inc.
Age Related Macular Degeneration, Choroidal Neovascularization
Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD).
- Trial name
- NCT01336907
- Where
- France
- Sponsor
- Notal Vision Ltd.